NY-THE-ROHATYN-GROUP
13.7.2022 14:02:12 CEST | Business Wire | Press release
The Rohatyn Group (“TRG”), a global asset management firm, today announced that it has completed the acquisition of electric bicycles (“e-bikes”) producer Leader 96 EOOD (“Leader” or the “Company”), from KJK Capital (“KJK”), establishing a partnership with Dimitar Zlatanov, the Company’s CEO and member of the founding family. TRG’s ownership can allow Leader to rapidly accelerate its e-bike production and broaden its product offering to address burgeoning demand from customers across Europe. Terms of the transaction were not disclosed.
Founded in 1996 in Plovdiv, Bulgaria, Leader is a leading producer of e-bikes in Europe with sales across the continent. The Company produces a broad range of e-bikes including touring, trekking, mountain, folding and gravel bike models. The Company is planning to launch a new e-cargo bike in 2023.
“Leader is a highly attractive business that provides a unique and high-quality product offering in the European e-bike sector. The Company is well-positioned to benefit from the continuing transformation of city transport infrastructures towards bicycle-friendly zones, increased demand for practical eco-friendly transportation and shared bike programs, as well as the growth of last-mile micro-delivery. Additionally, an increasing focus on healthier lifestyles means e-bikes can offer a highly democratic exercise solution across a wide spectrum of age and fitness levels,” said TRG’s Colin Clark, Partner and Head of EMEA Private Markets, and Stepan Karpukhin, Managing Director, who led the deal alongside Stanislav Bachvarov, Director.
“Leader is a high-growth business with an international profile that fits in perfectly with TRG’s global approach. We strongly believe that the Company has the potential to be a leading player in the e-bike sector thanks to its focus on customer service and forward-thinking approach to technology,” added Nick Rohatyn, CEO of TRG. “We believe increased adoption of e-bikes can contribute to societal progress towards more sustainable urban development, reduction of carbon emissions, and healthier lifestyles, and are proud to invest in a company that recognizes the significance of a positive environmental impact. We look forward to delivering strong growth alongside Dimitar and his team.”
Dimitar Zlatanov, CEO and member of the founding family, commented, “I am tremendously proud of the growth Leader has already achieved, as we have transformed our business into a leading e-bike producer in Europe. We look forward to continuing our growth in partnership with The Rohatyn Group and leveraging the team’s expertise.”
Kustaa Aima, Managing Partner at KJK Capital added “Leader is a great company that transformed through our period of ownership into a leading European e-bike producer. We wish both TRG and Dimitar Zlatanov all the best and look forward hearing more about the Company’s strong growth in the years ahead.”
About TRG
Founded in 2002, The Rohatyn Group is an asset management firm focused on emerging markets and real assets, headquartered in New York, with a global presence in 16 cities across the US, Latin America, Europe, the Middle East, India and Southeast Asia. For more information, please visit www.rohatyngroup.com
About KJK
Founded in 2010, KJK Capital is an independent, partner owned, private equity manager focused on European Frontier markets with a combined assets under management of EUR 600 million. With main offices in Helsinki, Vilnius and Luxembourg, KJK has also local representation in Estonia, Slovenia, Croatia, Bulgaria and Romania. For more information about KJK, please visit www.kjkcapital.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220713005286/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom